BiotechTube
OncoAssure

OncoAssure

Dublin, Ireland· Est.
oncoassure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

OncoAssure is a private, pre-revenue diagnostics company developing precision oncology tests, with an initial focus on prostate cancer. The company leverages a proprietary process combining transcriptomics and mathematical modeling to identify key drivers of cancer progression and generate prognostic biomarkers. With a management team experienced in diagnostic development and commercialization—including a prior successful exit via acquisition by Cepheid—OncoAssure is advancing its lead test through clinical validation and U.S. launch activities while seeking further investment.

Oncology

Technology Platform

Proprietary process combining transcriptomics and mathematical modeling to identify key drivers of cancer progression and develop prognostic gene expression signatures for multiple cancer types.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The significant unmet need in prostate cancer for better risk stratification to reduce overtreatment presents a large addressable market.
The team's prior success in developing and exiting a breast cancer test (OncoMasTR) validates their platform and creates a potential roadmap for partnership or acquisition.
The technology platform is also applicable to other cancer types, allowing for future pipeline expansion.

Risk Factors

Key risks include commercial adoption challenges in a competitive prostate cancer diagnostics market, dependence on successful fundraising to execute the business plan, and the need to generate extensive clinical evidence and secure favorable reimbursement for the test.

Competitive Landscape

OncoAssure competes in the molecular diagnostics for prostate cancer space against established commercial tests like Decipher Prostate (Veracyte), Oncotype DX GPS (Exact Sciences), and Prolaris (Myriad Genetics). Differentiation will rely on the clinical utility, cost, ease of use, and strength of validation data for its specific gene signature.

More companies in Diagnostics & Precision Medicine →More companies in Ireland →